Stockscreener 앱 받기
125.77
0.55%
0.69
전일 마감가:
$125.08
열려 있는:
$125.22
하루 거래량:
1.12M
Relative Volume:
0.32
시가총액:
$27.47B
수익:
$819.56M
순이익/손실:
$-1.18B
주가수익비율:
-21.90
EPS:
-5.7434
순현금흐름:
$-951.64M
1주 성능:
+1.64%
1개월 성능:
+15.79%
6개월 성능:
-23.73%
1년 성능:
-5.15%
1일 변동 폭
$124.82
$127.20
1주일 범위
$124.60
$131.10
52주 변동 폭
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
명칭
Insmed Inc
전화
908-977-9900
주소
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
125.77 | 27.32B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2026-03-30 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2025-12-19 | 재개 | Truist | Buy |
| 2025-12-04 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-28 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-08-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 개시 | Jefferies | Buy |
| 2025-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-23 | 개시 | Truist | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-07-26 | 개시 | Guggenheim | Buy |
| 2022-12-09 | 개시 | Mizuho | Buy |
| 2022-12-07 | 개시 | Barclays | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Buy |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2021-12-06 | 개시 | JP Morgan | Overweight |
| 2021-10-19 | 재개 | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-10-12 | 재개 | Stifel | Buy |
| 2019-09-03 | 개시 | Goldman | Buy |
| 2019-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-15 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-01-02 | 개시 | Canaccord Genuity | Buy |
| 2018-08-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 개시 | Goldman | Neutral |
| 2018-04-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 개시 | Morgan Stanley | Overweight |
| 2018-01-18 | 개시 | Credit Suisse | Neutral |
| 2017-09-05 | 재확인 | Evercore ISI | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Robert W. Baird | Outperform |
| 2016-03-15 | 개시 | Stifel | Buy |
| 2015-11-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2015-10-06 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-09 | 개시 | Citigroup | Neutral |
| 2014-03-26 | 재확인 | HC Wainwright | Buy |
모두보기
Insmed Inc 주식(INSM)의 최신 뉴스
Insmed (INSM) Q2 2026 Earnings Call Transcript - AOL.com
Biotech Is Booming, But These 2 Stocks Missed the Memo - Sahm
Insmed Slides 4.3% as Recent Insider Sales and Post-Earnings Profit-Taking Weigh on Shares - Quiver Quantitative
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Insmed Director Melvin Sharoky Reports Sale of 5,000 Shares via Padonia, LLC - Kalkine Media
Insmed Insider Sold Shares Worth $637,650, According to a Recent SEC Filing - marketscreener.com
Insmed (NASDAQ: INSM) director sells 5,000 shares via Padonia LLC - Stock Titan
How Insmed’s Sharply Narrowed Q2 2026 Net Loss At Insmed (INSM) Has Changed Its Investment Story - simplywall.st
BMO Capital Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $192 - Moomoo
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - stocktwits.com
Insmed (NASDAQ: INSM) holder Padonia targets $638K share sale - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Insmed CMO Martina Flammer sells $3.49m in company stock By Investing.com - Investing.com Australia
Insmed CMO Martina Flammer sells $3.49m in company stock - Investing.com
H.C. Wainwright Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $220 - Moomoo
13,000 Shares in Insmed, Inc. $INSM Purchased by S&CO Inc. - MarketBeat
Insmed, Inc. $INSM Shares Bought by Empowered Funds LLC - MarketBeat
Insmed Stock Price Forecast. Should You Buy INSM? - StockInvest.us
Darwin Global updates Insmed Inc (INSM) ownership, reporting 3.0% beneficial stake - Stock Titan
INSM|Insmed Inc|Price:123.740|Chg%:-2.590 - TradingKey
Insmed(INSM.US) Officer Sells US$31.96 Million in Common Stock - moomoo.com
FY2026 Earnings Forecast for Insmed Issued By HC Wainwright - MarketBeat
Handelsbanken Fonder AB Grows Stake in Insmed, Inc. $INSM - MarketBeat
Insmed (NASDAQ:INSM) COO Sells 239,850 Shares - MarketBeat
Insmed Insider Sold Shares Worth $31,964,810, According to a Recent SEC Filing - marketscreener.com
Insmed Chief Operating Officer Sold Shares Worth Over $31M - TradingView
INSMED Inc (INSM) COO exercises 239,850 options and sells matching shares - Stock Titan
HC Wainwright Brokers Increase Earnings Estimates for Insmed - MarketBeat
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024 - kalkine.ca
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Minerva Neurosciences (NERV) and Zymeworks (ZYME) - The Globe and Mail
INSM (INSM) insider notice covers 239,850 shares and prior sales data - Stock Titan
INSM Maintained by JP Morgan -- Price Target Lowered to $175 - GuruFocus
Insmed (NASDAQ:INSM) Price Target Cut to $175.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
INSM Reiterates by Truist Securities -- Price Target Raised to $195 - GuruFocus
$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today - Benzinga
H.C. Wainwright reiterates Buy on Insmed stock, $220 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Buy on Insmed stock, $220 target - Investing.com India
High Growth Tech Stocks in the US to Watch - simplywall.st
Pacer Advisors Inc. Has $1.19 Million Holdings in Insmed, Inc. $INSM - MarketBeat
Assenagon Asset Management S.A. Acquires 155,011 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed Inc (INSM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insmed (NASDAQ:INSM) Posts Earnings Results - MarketBeat
Insmed (INSM) Stock Cools As BRINSUPRI Surge Recasts Growth Profile - simplywall.st
Insmed Insider Sold Shares Worth $3,494,838, According to a Recent SEC Filing - marketscreener.com
INSM Maintained by Guggenheim -- Price Target Lowered to $205 - GuruFocus
Insmed slips as investors digest a sharp post-earnings rally - Quiver Quantitative
INSM Maintained by Wells Fargo -- Price Target Raised to $169 - GuruFocus
Insmed Outlook Strengthens After Q2 Results, RBC Says - Yahoo Finance
What Insmed Stock’s Premium Is Actually Buying - Trefis
INSM Maintained by Evercore ISI Group -- Price Target Raised to $170 - GuruFocus
Has Insmed (INSM) Risen Above Fair Value After Its 3 Year Run? - Yahoo Finance
Insmed Inc (INSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
1.07%
자본화:
|
볼륨(24시간):